Homepage Featured News
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
Reimbursement supports expanded access to blood-based comprehensive genomic profiling with Guardant360 CDx for patients with advanced solid tumor cancers and their care teams across Japan
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
With new coverage from Anthem Blue Cross and Blue Shield, Aetna and Humana, Guardant360 CDx/Guardant360 liquid biopsy test now covered by all major commercial health insurers
Guardant Health Releases Inaugural ESG Report
The publication of its inaugural Environmental, Social & Governance (ESG) Report, which provides information related to key ESG commitments that the company has laid out as part of its business strategy
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
Shield ™ blood test achieved overall 83% sensitivity and 90% specificity and demonstrated early-stage detection in range with other guideline-recommended non-invasive CRC screening modalities
Guardant Health Announces Additions to Leadership Team
At Guardant, we have built one of the most transformative platforms in diagnostics and we think extensively about how we get work done more efficiently, from development through delivery, to fulfill our primary mission of helping patients
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
Project will identify genomic and epigenomic biomarkers in patient blood samples from PICI’s RADIOHEAD study using GuardantINFINITY™
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
The data from the pivotal ECLIPSE Study accepted as a late-breaking abstract highlights the performance of the Shield ™ blood test in detecting colorectal cancer in asymptomatic patients
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
Live audio of the webcast will be available on the “Investors” section of the company website. The webcast will be archived and available for replay after the event.
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
First blood-only liquid biopsy test for monitoring molecular response to immune checkpoint inhibitors now covered for US Medicare patients with metastatic or inoperable solid tumors